CDx Precision Health

- Consultancy Leadership -

As a senior business executive at CDx Precision Health, Alan K. Hauser is championing valuation-led risk/reward economic decision analysis for clients in the CDx-stratified medicine sector. Being an accomplished life sciences corporate development leader and Certified Licensing Professional, Dr. Hauser has a successful track record of commercializing innovative genomics-driven drug-discovery and in-vitro diagnostics detection platforms.

Alan K. Hauser, Ph.D.

CRC2014-1675finalbw

Alan K. Hauser has helped launch 9 groundbreaking genomics products into the marketplace and build 4 biotool businesses resulting in, e.g., ACLARA’s $189 MM IPO. Since obtaining his doctorate in chemical and biomolecular engineering at U.C. Berkeley, Alan completed the executive leadership program at Northwestern’s Kellogg Management Institute as well as additional finance courses at the University of Chicago and Harvard.

TOP-LEVEL PROFESSIONALS

UNPARALLELED FLEXIBILITY

OUTSTANDING VALUE

7

APV Bio-I2C*
Valuations
appraised at $1.7 billion

for facilitating corporate strategic planning & risk analysis yielding efficacious decision making & resource allocation.

12

product/IP roadmaps

for visualizing Bio-I2C landscapes as part of 7 client projects to drive build versus buy decision analysis

9

ground breaking genomic product launches

enabling stratified precision medicine

68

transactions closed

including 10 Rx compounds licensed & 3 M&A deals valued at $280 MM

4

biotool business units built

including a $189 MM Initial Public Offering

24

invited presentations

for catalyzing Bio-I2C domestically & abroad

*Innovation to Commercialization